3.8 Article

Growth- Differentiation Factor-15 for Long-Term Risk Prediction in Patients Stabilized After an Episode of Non-ST-Segment-Elevation Acute Coronary Syndrome

期刊

CIRCULATION-CARDIOVASCULAR GENETICS
卷 3, 期 1, 页码 88-U284

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCGENETICS.109.877456

关键词

follow-up studies; prognosis; acute coronary syndrome; growth-differentiation factor-15; risk assessment; stable coronary artery disease

资金

  1. German Ministry of Education and Research
  2. Swedish Heart-Lung Foundation
  3. Pharmacia and Upjohn

向作者/读者索取更多资源

Background - Growth-differentiation factor-15 (GDF-15) has emerged as a prognostic biomarker in patients with non-ST-segment-elevation acute coronary syndrome. This study assessed the time course and the long-term prognostic relevance of GDF-15 levels measured repetitively in patients with non -ST-segment-elevation acute coronary syndrome during 6 months after the acute event. Methods and Results - GDF-15 and other biomarkers were measured at randomization, after 6 weeks, and after 3 and 6 months in 950 patients with non-ST-segment-elevation acute coronary syndrome included in the FRagmin and Fast Revascularization during InStability in Coronary artery disease II study. Study end points were death, recurrent myocardial infarction, and their composite during 5-year follow-up. Median GDF-15 levels decreased slightly from 1357 ng/L at randomization to 1302 ng/L at 6 months (P < 0.001). GDF-15 was consistently related to cardiovascular risk factors and biochemical markers of hemodynamic stress, renal dysfunction, and inflammation. Moreover, GDF-15 was independently related to the 5-year risk of the composite end point when measured at both 3 months (adjusted hazard ratio, 1.8 [1.0 to 3.0]) and 6 months (adjusted hazard ratio, 2.3 [1.3 to 4.1]). Serial measurements of GDF-15 at randomization and 6 months helped to identify patient cohorts at different levels of risk, with patients with persistently elevated GDF-15 levels > 1800 ng/L having the highest rate of the composite end point. Conclusions - GDF-15 is independently related to adverse events in non-ST-segment-elevation acute coronary syndrome both in the acute setting and for at least 6 months after clinical stabilization. Therefore, continued research on GDF-15 should be focused on the usefulness of GDF-15 for support of clinical management in acute and chronic ischemic heart disease. (Circ Cardiovasc Genet. 2010;3:88-96.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据